Page last updated: 2024-12-05

perflexane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Perflexane, also known as perfluorocarbon (PFC) emulsion, is a synthetic, inert liquid that can dissolve large amounts of oxygen. It is used in medical applications, particularly as a blood substitute, to enhance oxygen delivery to tissues. Its unique properties, including its high oxygen-carrying capacity and its ability to remain in the bloodstream for extended periods, make it a promising agent for treating conditions such as anemia and trauma. Perflexane is also being investigated for its potential in organ preservation and as a contrast agent in imaging. The compound is synthesized through a multi-step process involving the fluorination of hydrocarbons. Research into perflexane focuses on understanding its biocompatibility, its long-term effects on the body, and its efficacy in various clinical settings.'

perfluorohexane : A fluoroalkane that is hexane in which all of the hydrogens have been replaced by fluorines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9639
CHEMBL ID1200607
CHEBI ID39427
SCHEMBL ID33789
MeSH IDM0210692

Synonyms (72)

Synonym
hexane, tetradecafluoro-
perfluoro-n-hexane
perflexane [usan:inn]
fluorinert fc72
flutec pp1
af0150
einecs 206-585-0
perflexane (usan/inn)
355-42-0
D05437
afo145
PERFLEXANE-LIPID MICROSPHERES
n-perfluorohexane emulsion
imavist?
afo150
imagent?
NCGC00166122-01
tetradecafluorohexane, 99%
1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluorohexane
perfluorohexane
perflexane
tetradecafluorohexane
n-tetradecafluorohexane
CHEBI:39427 ,
n-perfluorohexane
CHEMBL1200607
af-0150
zjijajxflbmlck-uhfffaoysa-
inchi=1/c6f14/c7-1(8,3(11,12)5(15,16)17)2(9,10)4(13,14)6(18,19)20
AKOS005258316
unii-fx3wj41cmx
hexane, 1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluoro-
fx3wj41cmx ,
hsdb 7871
dtxsid7046548 ,
tox21_112328
cas-355-42-0
dtxcid5026548
A822857
P0839
fluorinert(r) fc-72
fluorinert(tm) (fc-72)(r)
flutecr pp
perfluorohexanes
perfluorohexane(s)
fluorinertr(fc-72)
perfluoro-compound fc-72
fluorinert fc-72
fc-72
FT-0676292
BP-21389
SCHEMBL33789
perflexane [usan]
perfluorohexane [inci]
perflexane [inn]
perflexane [orange book]
perfluorohexane [mi]
perflexane [mart.]
perflexane [who-dd]
perflexane [vandf]
af 0150
1,1,1,2,2,3,3,4,4,5,5,6,6,6-tetradecafluorohexane #
pp 1 (fluorocarbon)
W-109529
c6f14
mfcd00000437
Q3291714
DB09531
per-fluorohexane
D92023
AS-56640
fluorinert fc72fluorinert fc72

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" PFOS was the most toxic and PFHxA the least cytotoxic."( In vitro and in silico modeling of perfluoroalkyl substances mixture toxicity in an amphibian fibroblast cell line.
Guffey, S; Hoover, G; Kar, S; Leszczynski, J; Sepúlveda, MS, 2019
)
0.51
" The stimuli led to encapsulated DOX's initial burst release and subsequent sustained release for anti-tumor therapy which was verified to be more effective and have less adverse effects than free DOX."( Targeted and pH-facilitated theranostic of orthotopic gastric cancer via phase-transformation doxorubicin-encapsulated nanoparticles enhanced by low-intensity focused ultrasound (LIFU) with reduced side effect.
Liu, Z; Ran, H; Wang, Y; Wang, Z; Zhou, S, 2019
)
0.51
"Per- and poly-fluoroalkyl substances (PFAS) are a broad class of environmentally persistent chemicals that include thousands of potentially toxic synthetic organic molecules."( Chronic Reproductive Toxicity of Perfluorooctane Sulfonic Acid and a Simple Mixture of Perfluorooctane Sulfonic Acid and Perfluorohexane Sulfonic Acid to Northern Bobwhite Quail (Colinus virginianus).
Anderson, TA; Dennis, NM; Field, JA; Karnjanapiboonwong, A; McCarthy, C; Rewerts, JN; Salice, CJ; Subbiah, S, 2020
)
0.56
" Characterizing the chronic toxicity of individual PFAS compounds and mixtures is necessary because many have been reported to cause adverse health effects."( Species- and Tissue-Specific Chronic Toxicity Values for Northern Bobwhite Quail (Colinus virginianus) Exposed to Perfluorohexane Sulfonic Acid and a Binary Mixture of Perfluorooctane Sulfonic Acid and Perfluorohexane Sulfonic Acid.
Anderson, TA; Crago, JP; Dennis, ML; Dennis, NM; Hossain, F; Jackson, WA; Karnjanapiboonwong, A; McCarthy, C; Salice, CJ; Subbiah, S, 2022
)
0.72
" Body mass was the most sensitive endpoint, showing clear and biologically meaningful population level adverse effect sizes (≥20% adverse effects)."( A Critical Review of Amphibian Per- and Polyfluoroalkyl Substance Ecotoxicity Research Studies: Identification of Screening Levels in Water and Other Useful Resources for Site-Specific Ecological Risk Assessments.
Allmon, E; Choi, Y; Conder, J; Hoskins, T; Hoverman, J; Lee, L; Pandelides, Z; Sepúlveda, M, 2023
)
0.91
" In contrast, exposure to 6:2FTSA did not result in adverse transcriptomic effects, suggesting that 6:2FTSA exerted the least molecular-scale toxicity in earthworms."( Are PFBS, PFHxS, and 6:2FTSA more friendly to the soil environment compared to PFOS? A new insight based on ecotoxicity study in soil invertebrates (Eisenia fetida).
Du, Z; Juhasz, A; Li, B; Li, D; Liu, X; Wang, J; Wang, X; Zhang, J; Zhu, L, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The study of human toxicokinetics and physiologically based pharmacokinetic (PBPK) modeling of PFHxS has been less robust and has been limited in scope and application as compared to PFOS and PFOA."( Physiologically based pharmacokinetic (PBPK) modeling of perfluorohexane sulfonate (PFHxS) in humans.
Sweeney, LM, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Gated MRI studies were performed within 48 hours of dosing in a subset of 26 subjects."( Imagent improves endocardial border delineation, inter-reader agreement, and the accuracy of segmental wall motion assessment.
Dittrich, HC; Hall, G; Kitzman, DW; Nanda, NC, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
non-polar solventnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
fluorocarbonCompounds consisting wholly of fluorine and carbon.
fluoroalkaneA haloalkane that is an alkane in which at least one hydrogen atom has been replaced by a fluorine atom.
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (252)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (2.38)18.2507
2000's42 (16.67)29.6817
2010's121 (48.02)24.3611
2020's83 (32.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.52 (24.57)
Research Supply Index5.58 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (1.54%)5.53%
Reviews5 (1.92%)6.00%
Case Studies1 (0.38%)4.05%
Observational1 (0.38%)0.25%
Other249 (95.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]